AbbVie Grants Mylan License for Humira Biosimilar

AbbVie granted a non-exclusive license to Mylan for its proposed biosimilar for AbbVie’s immunosuppressive drug Humira (adalimumab) covering the United States and other countries around the world, but excluding Europe.

The U.S. license will begin on July 31, 2023 and Mylan will pay royalties to AbbVie once its biosimilar product is launched.

Humira is indicated for treatment of arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.